Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - KERYX BIOPHARMACEUTICALS INC | d141367dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 29, 2016
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-30929 | 13-4087132 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
One Marina Park Drive, 12th Floor
Boston, Massachusetts 02210
(Address of Principal Executive Offices)
(617) 466-3500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
| Item 8.01 | Other Events. |
On March 29, 2016, Keryx Biopharmaceuticals, Inc. issued a press release in which it reported topline results from its Phase 3 study of ferric citrate, an oral, iron-based medicine in development for the treatment of iron deficiency anemia in adults with stage 3-5 non-dialysis dependent chronic kidney disease.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements And Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press Release of Keryx Biopharmaceuticals, Inc., dated March 29, 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Keryx Biopharmaceuticals, Inc. | ||||
| (Registrant) | ||||
| Date: March 29, 2016 | ||||
| By: | /s/ Brian Adams | |||
| Brian Adams | ||||
| General Counsel and Corporate Secretary | ||||
INDEX TO EXHIBITS
| Exhibit |
Description | |
| 99.1 | Press Release of Keryx Biopharmaceuticals, Inc., dated March 29, 2016. | |